Edward Morrow Iii Atkinson Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 4 days, 13 hours ago
Edward Morrow Iii Atkinson has an estimated net worth of at least $16.9 million*, as of April 9, 2025. They own 19,352 shares of VRTX stock. They have sold 33,500 shares of VRTX stock since 2021, for an estimated $8.0 million.
Edward Morrow Iii Atkinson $VRTX SEC Form 4 Insider Trading
Edward Morrow Iii Atkinson has filed a total of 8 insider trades in $VRTX since 2021. Their most recent trade was a sale of 2,650 shares, made on Feb 27, 2025. Their largest trade was a sale of 7,288 shares, made on Jun 12, 2024. We estimate that they now own 19,352 shares of $VRTX, worth an estimated $8.9 million.
Insider Trading at $VRTX
There have been a total of 493 insider trades reported at $VRTX since 2021, with 25,000 shares purchased and 847,189 shares sold. The most active insider traders in $VRTX stock have been David Altshuler, Bastiano Sanna, and Ourania Tatsis. The most recent trade was a sale of 3,231 shares reported by DAVID ALTSHULER (EVP, Chief Scientific Officer), made on Mar 13, 2025.
History of Insider Stock Trades by Edward Morrow Iii Atkinson
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
VRTX
|
Sale | 2,650 | Feb 27, 2025 | Feb. 28, 2025, 5:36 p.m. |
|
VRTX
|
Sale | 1,767 | Feb 25, 2025 | Feb. 26, 2025, 5:09 p.m. |
|
VRTX
|
Sale | 1,747 | Feb 11, 2025 | Feb. 12, 2025, 5:29 p.m. |
|
VRTX
|
Sale | 7,288 | Jun 12, 2024 | June 13, 2024, 4:09 p.m. |
|
VRTX
|
Sale | 883 | Feb 26, 2024 | Feb. 27, 2024, 5:44 p.m. |
|
VRTX
|
Sale | 1,201 | Feb 21, 2024 | Feb. 23, 2024, 5:16 p.m. |
|
VRTX
|
Sale | 801 | Feb 20, 2024 | Feb. 21, 2024, 5:23 p.m. |
|
VRTX
|
Sale | 913 | Feb 12, 2024 | Feb. 13, 2024, 5:54 p.m. |
ETNB
|
Sale | 6,250 | Jun 01, 2023 | June 5, 2023, 5:03 p.m. |
|
ETNB
|
Sale | 10,000 | Mar 01, 2023 | March 3, 2023, 6:18 p.m. |
$VRTX Executives and Stock Owners with Insider Trades
-
David Altshuler, EVP, Global Research and CSO
-
Bastiano Sanna, EVP, Cell & Genetic Therapies
-
Ourania Tatsis, EVP, Chief Reg. & Quality Off.
-
Stuart A Arbuckle, EVP, COO
-
Charles F Jr Wagner, EVP & Chief Financial Officer
-
Jeffrey M Leiden, Executive Chairman
-
Joy Liu, SVP, General Counsel
-
Reshma Kewalramani, CEO & President
-
Kristen Ambrose, SVP & Chief Accounting Officer
-
Carmen Bozic, EVP and CMO
-
David Altshuler, EVP, Chief Scientific Officer
-
Edward Morrow Iii Atkinson, EVP, Chief Technical Ops. Off.
-
Amit Sachdev, EVP Chief Patient & Ext Af Off
-
Jonathan Biller, EVP and Chief Legal Officer
-
Amit Sachdev, EVP, Chief Patient Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.